CLNN Profile
Clene Inc. (CLNN) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel nanocatalytic technology-based therapeutics for the treatment of neurodegenerative diseases. The company is based in Maryland, USA, and was founded in 2013.
Clene's lead drug candidate, CNM-Au8, is a gold nanocrystal-based therapeutic that has been designed to address the underlying pathophysiology of several neurodegenerative diseases, including Alzheimer's and Parkinson's disease. CNM-Au8 has demonstrated significant improvements in biomarkers of neurodegeneration in preclinical models, and early-stage clinical trials have also shown positive results. The company is also exploring the potential of CNM-Au8 in the treatment of other neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
Clene is also developing several other drug candidates using its proprietary nanocatalytic technology platform, which enables the targeted delivery of active therapeutic agents to specific cells and tissues in the body. The company's pipeline includes drugs for the treatment of acute respiratory distress syndrome (ARDS), cancer, and metabolic disorders.
Clene has partnered with several academic institutions, including Johns Hopkins University and the University of Maryland, to support the development of its drug candidates. The company has also received funding from the National Institutes of Health (NIH) and the Michael J. Fox Foundation for Parkinson's Research.
In summary, Clene Inc. is a clinical-stage biopharmaceutical company focused on developing novel nanocatalytic technology-based therapeutics for the treatment of neurodegenerative diseases. Its lead drug candidate, CNM-Au8, has demonstrated positive results in early-stage clinical trials for the treatment of Alzheimer's and Parkinson's disease, and the company is also exploring its potential for the treatment of other neurodegenerative disorders. Clene is also developing several other drug candidates using its proprietary nanocatalytic technology platform.
|
